Alfresa Holdings Corporation Stock

Stocks

2784

JP3126340003

Medical Equipment, Supplies & Distribution

OTC Markets Traded
Market Closed - Japan Exchange 14:30:00 22/06/2026 HKT 5-day change 1st Jan Change
2,185.00 JPY +0.02% Intraday chart for Alfresa Holdings Corporation -0.93% -10.12%
Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Alfresa Holdings Corporation

Market Cap 397B 2.46B 2.15B 1.99B 1.86B 3.48B 232B 3.51B 23.63B 9.19B 114B 9.24B 9.04B P/E 2026
11x
P/E 2027 * 16.8x
Enterprise Value 397B 2.46B 2.15B 1.99B 1.86B 3.48B 232B 3.51B 23.63B 9.19B 114B 9.24B 9.04B EV / Sales 2026
0.15x
EV / Sales 2027 * 0.13x
Free-Float
88.28%
Yield 2026
2.69%
Yield 2027 * 3.25%
05-27 Alfresa Holdings Corporation concluded a share transfer agreement to acquire Nagashima Medical Instruments Co., Ltd. from Nagashima Holdings Co., Ltd. CI
05-18 Alfresa Holdings Corporation's Equity Buyback announced on May 15, 2026, has closed with 6,307,800 shares, representing 3.47% for ¥14,999.95 million. CI
05-18 Tranche Update on Alfresa Holdings Corporation's Equity Buyback Plan announced on May 15, 2026. CI
05-15 Alfresa Holdings Corporation authorizes a Buyback Plan. CI
05-15 Alfresa Holdings Corporation announces an Equity Buyback for 6,307,800 shares, representing 3.46% for ¥14,999.95 million. CI
05-15 Alfresa Holdings Corp - to buy back up to 3.5% of own shares worth about 15 billion yen RE
05-15 Alfresa Holdings Corporation Announces Cash Dividend for the Year-End of the Fiscal Year Ended March 31, 2026, Payable on June 2, 2026; Provides Cash Dividend Guidance for the Second Quarter-End and Year-End of the Fiscal Year Ending March 31, 2027 CI
05-15 Alfresa Holdings Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and for the Fiscal Year Ending March 31, 2027 CI
04-07 Healios Secures 144 Million Yen Initial Order from Alfresa's Korean Unit for Cosmetic Raw Material MT
02-27 Alfresa Holdings Corporation concluded a share transfer agreement to acquire Techno Suzuta, Co.,Ltd. from Onsendo, K.K. CI
02-10 Alfresa Books 15.4 Billion Yen Gain from Sale Of Investment Securities MT
02-10 Alfresa Holdings Corporation Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
02-02 ARS Pharmaceuticals Announces EURneffy 1 Mg (Adrenaline Nasal Spray) Recommended For Approval In The EU For Emergency Treatment Of Type 1 Allergic Reactions In Children Weighing 15 Kg To Less Than 30 Kg CI
1 day+0.02%
1 week-0.93%
Current month-2.24%
1 month-2.56%
3 months-9.71%
6 months-10.49%
Current year-10.12%
1 week 2,163
Extreme 2163
2,219
1 month 2,106.5
Extreme 2106.5
2,270
Current year 2,106.5
Extreme 2106.5
2,685.5
1 year 1,945.5
Extreme 1945.5
2,685.5
3 years 1,897
Extreme 1897
2,685.5
5 years 1,505
Extreme 1505
2,685.5
10 years 1,505
Extreme 1505
3,350
Manager TitleAgeSince
Chief Executive Officer 63 -
Chief Tech/Sci/R&D Officer 63 28/06/2022
Corporate Officer/Principal 61 01/04/2020
Director TitleAgeSince
Director/Board Member 63 01/06/2007
Director/Board Member 65 25/06/2025
Director/Board Member 50 01/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%-0.93%+11.03%-1.86% 2.46B
-0.27%-0.54%-33.82%-18.53% 154B
+0.07%-1.13%-7.54%-9.08% 102B
-0.99%+2.10%+59.76%+56.65% 56.51B
+0.01%-3.59%-7.44%+44.42% 52.89B
-1.86%-2.79%-16.65%-45.18% 39.67B
-1.35%-5.36% - - 30.39B
-4.84%-7.10%-13.64%-45.50% 27.96B
+0.33%-0.96%+51.48%-10.96% 23.17B
+0.90%+2.05%-14.45%-4.79% 20.35B
Average -0.80%-1.26%+3.19%-3.87% 50.9B
Weighted average by Cap. -0.60%-1.24%-6.49%-3.44%

Financials

2026 2027 *
Net sales 3,099B 19.2B 16.78B 15.52B 14.48B 27.19B 1,814B 27.39B 184B 71.74B 892B 72.08B 70.52B 3,164B 19.61B 17.13B 15.85B 14.79B 27.77B 1,853B 27.97B 188B 73.27B 911B 73.61B 72.01B
Net income 37.04B 229M 201M 185M 173M 325M 21.69B 327M 2.2B 858M 10.66B 862M 843M 25.25B 156M 137M 126M 118M 222M 14.78B 223M 1.5B 585M 7.27B 587M 574M
Net Debt - -
Logo Alfresa Holdings Corporation
Alfresa Holdings Corporation is a Japan-based holding company primarily engaged in the wholesale of drugs. The Company operates in four business segments. The Pharmaceutical Wholesale segment is engaged in the wholesale of medical products, test reagents, as well as medical equipment and materials. The Self Medication Wholesale segment is engaged in the wholesale of general drugs. The Pharmaceutical Manufacture segment is engaged in the manufacture and sale of pharmaceuticals, test reagents, medical equipment and implements, as well as pharmaceutical powders. The Medical-Related segment is mainly engaged in operation of pharmacies. The others business is engaged in the information system business, the transportation business, the warehousing business, the insurance agency business, the real estate management business, the sale of miscellaneous goods, as well as the manpower dispatching business, among others.
Employees
12,452
Date Price Change Volume
22/06/26 2,185.00 ¥ +0.02% 394,800
19/06/26 2,184.50 ¥ +0.74% 771,700
18/06/26 2,168.50 ¥ -0.62% 575,700
17/06/26 2,182.00 ¥ -0.66% 476,700
16/06/26 2,196.50 ¥ -0.16% 459,800
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
2,185.00JPY
Average target price
2,500.00JPY
Spread / Average Target
+14.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2784 Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!